mRNA therapies on the rise

The Aidaptus® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and manufacturing support provided by Stevanato Group.

SG Alina is a variable-dose and fixed-dose and pen injector offered by Stevanato Group in collaboration with Cambridge Design Partnership.
It is based on Axis-D intellectual property and technology exclusively licensed from pen injector device expert Haselmeier, for the treatment of diabetes.

Leveraging the established EZ-fill® market leading technology, process, and product optimisation to improve quality, reduce total cost of ownership, and shorten lead times.

In this article, Stevanato Group discusses the challenges faced in administering highly viscous biologics to patients via subcutaneous injection and how its special thin-wall needles can tackle them.

The Company offers the platform as a readily customizable pre-filled and pre-loaded on-body solution for drug delivery. Device development is making significant progress, with samples expected to be available in 2023.

Discover how Stevanato Group helps pharma companies identify relevant testing to de-risk the product development lifecycle and quickly uncover the root causes of product failures.

Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPHI webinar, sponsored by Stevanato Group.

In this article, Stevanato Group, introduces Vertiva™️, the company’s next-generation on-body delivery system platform, and discusses how it meets the needs of pharma companies looking to deliver large-volume doses in a patient-centric manner.

Watch this recent webinar exploring the challenges of distributing COVID-19 vaccines to a global population and the role the packaging sector is playing to ensure safe and speedy distribution of shots

Lars Keinicke Hansen, Chiara Mussoi, and Odra Pinato, all of Stevanato Group, describe how the streamlining of processes and harmonisation of products and services can better serve pharmaceutical companies. A case study highlights how a unique combination of expertise in automation and glass primary packaging benefited pharma giant Merck Serono in a recent project.

The increasing number of complex and sensitive biologics and the administration shift from hospitals to patients' homes are two of today’s main biopharmaceutical industry challenges. Complex drugs and self-administration require an appropriate primary packaging selection from the beginning of the bio drug development process. In this article, you will learn how Stevanato Group can support biopharma companies in the container closure system choice leveraging its 70-year expertise in glass primary packaging, up to the integration into drug delivery systems, backed up by solid characterization analysis.

Stevanato Group

Patients suffering from chronic and acute pain disorders will benefit from a convenient, discreet, and easy-to-use device delivering a novel alternative to opioid-based pain management.

Assembly Equipment combining transport platforms and process modules: an offer of manual, semi-automatic or fully automatic assembly lines customized to your device program.

Due to begin operations in late September, the US TEC will bring value-added laboratory services to the heart of the biotech community.

A flexible mid-high speed pen injector line assembling different formats and integrating extensive in-process controls.

The Vision Robot Unit will provide biopharma companies with a fully automatized, highly accurate and flexible inspection system equipped with artificial intelligence for a variety of drug products, for increased operational efficiency.

The COVID-19 pandemic has placed a spotlight on the readiness and requirements of pharma packaging companies to support the distribution and delivery of a potential vaccine and selecting the most suitable primary packaging options for drug products is one of the most crucial considerations in the drug development process, according to industry experts speaking in this CPHI China Virtual Expo Connect Webinar, sponsored by Stevanato Group. Daniel Martinez, Product Manager, Stevanato Group pointed out that speed to market is a primary consideration for vaccine developers, particularly in the current pandemic environment, and keeping the same type of container is essential to reaching this target. “The advantage of using a vial is that it is a pretty versatile container – it’s good for liquids, it’s good for lyophilized products, powders and cryogenic,” he told the audience, noting that some of the COVID-19 vaccines being developed need to be stored at -70 degrees. Watch the webinar to hear more from Daniel and experts from NRL Enterprise Solutions & IQVIA.

In a compressed timeframe, producing large quantities of pharmaceutical glass containers to deliver the coronavirus vaccine around the world is a critical factor for a successful global response. Type 1 glass is a proven and widely available solution for pharma glass containers that preserves the stability of vaccines. Players in the pharmaceutical supply chain are committed to supporting pharmaceutical companies and governments in the fight against the pandemic.

This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Glass primary packaging solutions offer safety, stability, recyclability and protect drug integrity. The glass packaging market is predicted to grow exponentially in the next few years, driven in part by the huge demand for glass vials for COVID-19 vaccines. What are the emerging trends in this sector? Which ones are here to stay, or which will prove to be transitory? Unprecedented packaging demands: the impact of COVID19 on the glass packaging market Glass primary packaging to answer customers’ requirements Smart Containers: A new vision ahead for Pharmaceutical Packaging How can pharma manufacturers prepare for future trends?

Artificial Intelligence (AI) has triggered a fundamental shift within the innovation paradigm for the pharmaceutical industry and has been implemented in almost every aspect of the value chain, from drug discovery and development to manufacturing. One application of AI which offers particular value is the realm of visual inspections, which present a challenging step in the packaging process. This is particularly true for products with complex characteristics where manual inspections can sometimes fall short, leading to errors and inconsistencies. AI learning models can optimise the packaging process by detecting minute errors, resulting in fewer rejects, less intervention and a more efficient process overall. This webinar will tackle some of the key drivers and benefits to implementing AI for pharma visual inspections to enhance performance, improve accuracy, efficiency and overall quality. Why attend? Common challenges encountered with Pharma Visual Inspections Key Drivers and Benefits to Implementing AI for Pharma Visual Inspections Case Study: Enhancing Pharma Visual Inspection Processes with AI Validation of Artificial Intelligence (AI)-Based Systems WATCH FOR FREE

Advances in auto-injector design now provide the option to use both 1ml and 2.25mL syringes plus employ technology to adapt to varying fill volumes and viscosities all whilst maintaining the same device form. This provides a solution for the formulation changes that take place during drug development, clinical trials, and life cycle management. When looking at the performance of any parenteral injection device, the drug containment systems play a crucial role. Auto-injector performance and functionality is strictly linked to key dimensional tolerances of glass syringes. We will illustrate the importance of syringe design to ensure these requirements and how monitoring dimensional parameters at an early stage of the development is key to ensure the intended use and ultimately work to preserve patients’ safety. Benefits of tight collaboration between device designer and manufacturer will also be discussed.